经皮冠状动脉介入治疗成功后，没有什么地方比得上家。 - Suppr | 超能文献

There is no place like home after successful percutaneous coronary intervention.

作者信息

Gilchrist Ian C

出版信息

Catheter Cardiovasc Interv. 2009 Dec 1;74(7):1017-8. doi: 10.1002/ccd.22336.

DOI:10.1002/ccd.22336

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

There is no place like home after successful percutaneous coronary intervention.经皮冠状动脉介入治疗成功后，没有什么地方比得上家。

Catheter Cardiovasc Interv. 2009 Dec 1;74(7):1017-8. doi: 10.1002/ccd.22336.

2

Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.经桡动脉冠状动脉支架置入术后单纯阿昔单抗推注与推注联合输注的长期疗效比较

Catheter Cardiovasc Interv. 2009 Dec 1;74(7):1010-6. doi: 10.1002/ccd.22235.

3

The benefits and risks of abciximab, eptifibatide, or tirofiban during PCI: class effects or do they differ?在经皮冠状动脉介入治疗（PCI）期间使用阿昔单抗、依替巴肽或替罗非班的获益与风险：类效应还是存在差异？

Catheter Cardiovasc Interv. 2009 Feb 1;73(2):222-3. doi: 10.1002/ccd.21954.

4

A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.经皮冠状动脉血运重建和支架置入术中高剂量推注替罗非班与阿昔单抗和普通肝素与比伐卢定的随机两因素两水平比较：替罗非班新型给药方案与氯吡格雷联合阿昔单抗抑制血小板糖蛋白Ⅱb/Ⅲa 受体（TENACITY）研究。

Catheter Cardiovasc Interv. 2011 Jun 1;77(7):1001-9. doi: 10.1002/ccd.22876. Epub 2011 Jan 11.

5

Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.经皮冠状动脉介入治疗期间仅推注阿昔单抗、依替巴肽或替罗非班后的长期死亡率。

Catheter Cardiovasc Interv. 2009 Feb 1;73(2):214-21. doi: 10.1002/ccd.21773.

6

Outpatient percutaneous coronary interventions: hospital and health system costs saving while maintaining patient safety.门诊经皮冠状动脉介入治疗：在维持患者安全的同时节省医院和卫生系统成本。

JACC Cardiovasc Interv. 2010 Oct;3(10):1020-1. doi: 10.1016/j.jcin.2010.09.001.

7

The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.阿司匹林和氯吡格雷反应对经皮冠状动脉介入术后心肌坏死的影响：BRIEF-PCI（经皮冠状动脉介入成功后静脉注射依替巴肽短期输注）试验子研究

JACC Cardiovasc Interv. 2008 Dec;1(6):654-9. doi: 10.1016/j.jcin.2008.08.017.

8

Clopidogrel under scrutiny.

Catheter Cardiovasc Interv. 2008 Dec 1;72(7):925-6. doi: 10.1002/ccd.21871.

9

Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.糖蛋白IIb/IIIa抑制剂可改善氯吡格雷无反应者冠状动脉支架置入术后的预后：一项前瞻性随机研究。

JACC Cardiovasc Interv. 2008 Dec;1(6):649-53. doi: 10.1016/j.jcin.2008.08.018.

10

Bifurcation stenting: a commitment to always kiss.分叉支架置入术：始终保持贴靠的要求。

Catheter Cardiovasc Interv. 2010 Mar 1;75(4):614-5. doi: 10.1002/ccd.22486.

引用本文的文献

1

Same day discharge after elective percutaneous coronary intervention.择期经皮冠状动脉介入治疗后当日出院。

Curr Cardiol Rep. 2014 Apr;16(4):470. doi: 10.1007/s11886-014-0470-y.